Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q1 FY2019 Earnings Presentation
21 slides from Morepen Laboratories's earnings presentation, August 2018
Slide 1: Investors Presentation (Q1) August 2018
“ I CHOOSE INVESTORS PRESENTATION (q1) august 2018
Slide 2: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 3: Contents
Contents: 1. Highlights of Financial Performance for Q1’FY19 Page 4 2. API Business Page 6 3. Dr. Morepen Brand Portfolio Page 8 “ 4. Diagnostics Business Page 11 5. Branded Generics Page 13 6. OTC Products Page 15 7. Financials Page 17 8. Quarterly Results Page 20
Slide 4: Highlights of Q1'FY19 Performance
Highlights of Q1’FY19 Performance ₹ crores • Net Sales Revenue up by 26% at Rs. 161.81 crore backed by improved sales revenue from Home Diagnostics, Formulations and OTC Businesses. Domestic sales up by 71 % at Rs. 108.20 crore • Net Profit before tax up by 108 % at Rs. 2.65 crore. Net Profit after
Slide 5: Segments wise growth
Segments wise growth ₹ crores • Overall business for the Quarter (Q1’FY19) has grown at 24% as compared to Q1’FY18 164 • API Business has shown extremely good results in the domestic market having grown at 88% for the Q1’FY19 and still contributes 47% including exports. 24% • Home Diagnostic Devices
Slide 6: API Business
API Business Production Units P1-P10 in Baddi (HP) 6
Slide 7: API: Increasing Domestic topline
API: Increasing Domestic topline ₹ crores • Domestic API business has got a jump of 88% during the Q1’FY19 as compared to Q1’FY18 API Sales 78.00 • Montelukast has registered an jump of 55% in Q1’FY19 as compared to Q1’FY18 and contributes 30% to the API topline. Trial shipments to US markets have s
Slide 8: Branded Portfolio
Dr. Morepen® Health in your hands BrangeaPonioe
Slide 9: Dr. Morepen
Dr. Morepen®
Slide 10: Branded Portfolio
Branded Portfolio ₹ crores • Dr. Morepen brand basket has grown from Rs.48.81 crores to Rs. 84.23 crores for the Q1’FY19 and has registered an upside of 73% as compared Q1’FY18 • Within the basket, Diagnostic Devices business has shown has registered a growth of 51% while Finished Dosages has regist
Slide 11: Diagnostics Business
| Diagnostics Business Sy pe 4
Slide 12: Devices Business - Growth Driver
Devices Business - Growth Driver ₹ crores • Home Devices portfolio has been growing with fast pace and has recorded a growth of 51% during the quarter. • Blood Gluco Monitors have marked a growth of 78% in Q1’FY19 as against Q1’FY18. 34.58 Total Gluco monitors installed during Q1’FY19 were 48% more
Slide 13: Branded Formulations
MOREPEN The Joy Of Growing Together / AGI | arena Panto oy /-4\ 13
Slide 14: Finished Dosages: Record growth
Finished Dosages: Record growth ₹ crores • Finished Dosages has bounced back strongly with a record increase of 101% in Q1FY’19 as compared to last year same quarter. 36.34 • Branded Prescription (Rx) products has grown by 99% during the Q1’FY’19 101% • Antibiotics and Vitamins have grown by 133% an
Slide 15: Over The Counter - OTC
‘The Joy Of Growing Together
Slide 16: OTC Business: Bouncing Back
OTC Business: Bouncing Back ₹ crores 13.31 • Total OTC category has registered a robust growth of 69% during the quarter. • Lead Brands like Burnol (Burn Cream), Lemolate (Cough & Cold) and Fiber-X (Sat Isabgol) have registered a growth of 54% 69% • Burnol Sales have gone up strongly by 35% during t
Slide 17: Financials
MOREPEN ‘The Joy Of Growing Together INANE INES)
Slide 18: Increasing Cash Surplus
Increasing Cash Surplus ₹ crores 3.00 Net Profit after tax • EBIDTA number has grown up by 10.4% during the Quarter as compared to 2.53 2.50 corresponding Quarter last year 99% • 2.00 Drop in interest cost by 67%. Quantum jump in Cash Profits during Q1’FY19 and Cash surplus has increased by 21% as c
Slide 19: Becoming Debt Free soon
Becoming Debt Free soon ₹ crores 47.12 Debt Outstanding • The company had peak outstanding debt of Rs.750 crores with 43 banks in FY’05 which was restructured through CDR Scheme of RBI in July 2006. with an upfront payment of OTS amount of Rs.150 crores. • The residual debt of Rs.147 crores has been
Slide 20: Synopsis of Q1'FY19 Performance
Synopsis of Q1’FY19 Performance ₹ crores Consolidated Consolidated Y-o-Y Q1’FY19 Q1’FY18 Growth Net Revenue 163.74 132.04 24.2% Expenditure 151.49 120.94 25.3% EBIDTA 12.25 11.10 10.4% Interest 0.44 1.33 (66.6%) Cash Surplus 11.81 9.78 20.8% Dep. & Amortization 9.16 8.50 7.8% Income Tax 0.19 - Net P
Slide 21: Thank You
Tran You Fit MOREPEN ‘The Joy Of Growing Together
Morepen Laboratories — Q1 FY2019 Earnings Presentation on 6ix